Skip to main content
. 2017 Oct 19;10:5065–5076. doi: 10.2147/OTT.S142620

Figure 3.

Figure 3

Progression-free survival for patients with metastatic gastric cancer receiving chemotherapy and trastuzumab (A, P=0.004) or chemotherapy only (B, P=0.62) as the first-line treatment, according to FcγRIIA and IIIA polymorphisms (others vs H/H or V/V).

Abbreviation: FcγR, Fc γ receptor.